Review on clinical application of huperzine A in China
文献类型：期刊论文
| 作者 | YAN Han; TANG Xican
|
| 刊名 | Chinese Journal of New Drugs and Clinical Remedies
 |
| 出版日期 | 2006 |
| 卷号 | 25期号:9页码:682-688 |
| 关键词 | huperzine A Alzheimer disease dementia vascular memory cognition |
| ISSN号 | 1007-7669 |
| 其他题名 | 石杉碱甲国内临床应用回顾 |
| 文献子类 | Article |
| 英文摘要 | Several acetylcholinesterase inhibitors have been authorized for Alzheimer＇s disease （AD） therapy during recent years. Huperzine A is a novel alkaloid isolated from Chinese herb Huperzia serrata. As a potent, highly specific and reversible inhibitor for acetylcholinesterase of central nervous system, it has been proven preclinically to possess the ability to improve learning and memory in a broad range of animal models with cognitive deficits, and furthermore has been authorized for treating AD and benign memory deficits since 1994. With the extension of clinic application, huperzine A has been found to exert significant effect in the treatment of vascular dementia and cognitive deficits caused by other pathogenesis as well, indicating a prosperous fruitful future in clinic application. |
| 资助项目 | 国家自然科学基金[00000000] |
| WOS研究方向 | Pharmacology & Pharmacy (provided by Clarivate Analytics) |
| 语种 | 中文 |
| CSCD记录号 | CSCD:2574467 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/268184]  |
| 专题 | 院士及顾问专家 |
| 通讯作者 | TANG Xican |
| 作者单位 | State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, SHANGHAI 201203, China. |
| 推荐引用方式 GB/T 7714 | YAN Han,TANG Xican. Review on clinical application of huperzine A in China[J]. Chinese Journal of New Drugs and Clinical Remedies,2006,25(9):682-688. |
| APA | YAN Han,&TANG Xican.(2006).Review on clinical application of huperzine A in China.Chinese Journal of New Drugs and Clinical Remedies,25(9),682-688. |
| MLA | YAN Han,et al."Review on clinical application of huperzine A in China".Chinese Journal of New Drugs and Clinical Remedies 25.9(2006):682-688. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。